Thiogenesis Therapeutics
Thiogenesis Therapeutics is a clinical-stage biotechnology company focused on developing advanced sulfur-based thiol compounds to target oxidative stress and inflammation, key drivers of mitochondrial diseases. Their lead candidate, TTI-0102, is a cysteamine prodrug in Phase 2 trials for pediatric mitochondrial conditions, aiming to improve tolerability and dosing. The company is committed to addressing unmet medical needs in inherited and acquired mitochondrial diseases, leveraging proprietary compounds engineered to overcome traditional thiol drug limitations.
Industries
Nr. of Employees
small (1-50)
Thiogenesis Therapeutics
4 King Street West, Suite 401, Toronto, Ontario, Canada
Patents
Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders
US-11786491-B2
View DetailsCompositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders
US-11173135-B2
View Details
Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders
US-11786491-B2
View DetailsCompositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders
US-11173135-B2
View DetailsProducts
Lead cysteamine prodrug (proprietary thiol prodrug)
A synthesized asymmetric disulfide prodrug engineered to release an active thiol (cysteamine) through metabolism, intended to extend therapeutic availability, reduce peak-related side effects, and enable less frequent dosing compared with immediate-release thiol formulations.
Lead cysteamine prodrug (proprietary thiol prodrug)
A synthesized asymmetric disulfide prodrug engineered to release an active thiol (cysteamine) through metabolism, intended to extend therapeutic availability, reduce peak-related side effects, and enable less frequent dosing compared with immediate-release thiol formulations.
Expertise Areas
- Prodrug design and thiol chemistry
- Mitochondrial disease therapeutics
- Rare disease and pediatric clinical development
- Translational pharmacology and PK/PD
Key Technologies
- Thiol chemistry (R-SH functional group)
- Prodrug platform for controlled release of active thiols
- Glutathione precursor delivery
- Redox/thiol-disulfide balancing
News & Updates
Thiogenesis Therapeutics announced enrollment at a second trial site in France for its Phase 2 MELAS clinical trial.
Thiogenesis Therapeutics announced the initiation of its Phase 2 MELAS clinical trial.
Thiogenesis Therapeutics announced its listing on OTCQX in the United States.
Thiogenesis Therapeutics received final Clinical Trial Authorization (CTA) clearance for its Phase 2 MELAS trial.
Thiogenesis Therapeutics announced it will present at the UMDF Mitochondrial Medicine 2025 conference.
Thiogenesis Therapeutics announced the formation of its Scientific Advisory Board.
Thiogenesis Therapeutics announced enrollment at a second trial site in France for its Phase 2 MELAS clinical trial.
Thiogenesis Therapeutics announced the initiation of its Phase 2 MELAS clinical trial.
Thiogenesis Therapeutics announced its listing on OTCQX in the United States.
Thiogenesis Therapeutics received final Clinical Trial Authorization (CTA) clearance for its Phase 2 MELAS trial.
Thiogenesis Therapeutics announced it will present at the UMDF Mitochondrial Medicine 2025 conference.
Thiogenesis Therapeutics announced the formation of its Scientific Advisory Board.